Calcimedica Inc (CALC)

$4.57 -0.12 (-2.56%)
Market Cap 66.28M
Revenue (ttm) 0.00
Net Income (ttm) -13.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 40,100
Avg Vol 63,784
Day's Range N/A - N/A
Shares Out 14.41M
Stochastic %K 93%
Beta 0.58
Analysts Strong Sell
Price Target $17.00

Company Profile

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also d...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 952 5500
Address:
505 Coast Boulevard South, Suite 307, La Jolla, United States
Elegant_Confusion
Elegant_Confusion Dec. 5 at 12:06 AM
$CALC something looks fishy when somebody trades a stock after hours way below market, and just minutes before after hours trading closes. There is no news to explain such a dive in the price. CALC is a very thinly traded stock! Someone could be selling to themselves using two accounts. Then in premarket trading, offer to buy more at a lowball bid, and see how many scared sellers take you up on it.
0 · Reply
Elegant_Confusion
Elegant_Confusion Dec. 4 at 11:36 PM
$CALC can anyone assess the reason for the sudden 15% slump in the after hour’s price, which appears to have taken place just minutes before after hours trading closed? How much volume did it represent?
1 · Reply
Gashcooper
Gashcooper Dec. 4 at 9:46 PM
$CALC No complaints from me🤷🏾‍♂️ - https://m.investing.com/news/analyst-ratings/oppenheimer-reiterates-outperform-rating-on-calcimedica-stock-ahead-of-key-trial-93CH-4385648?ampMode=1
0 · Reply
InfinityVenom
InfinityVenom Dec. 4 at 4:13 PM
$CALC Multi year breakout happening now. $SPY $QQQ
1 · Reply
Tfizzle
Tfizzle Dec. 4 at 2:27 PM
$EP $TPVG $CALC big insider buying all of these $MAIA $PFE
0 · Reply
Tfizzle
Tfizzle Dec. 3 at 8:07 PM
$CALC yup
0 · Reply
InfinityVenom
InfinityVenom Dec. 3 at 4:12 PM
$CAPR Mark my WORDS. $CALC is NEXT
1 · Reply
Tfizzle
Tfizzle Dec. 3 at 3:40 PM
$CALC pullback. Slingshot engaged!
0 · Reply
InfinityVenom
InfinityVenom Dec. 2 at 9:07 PM
$CALC Hell yea boys
0 · Reply
sh64
sh64 Dec. 2 at 8:55 PM
$CALC it’s time
0 · Reply
Latest News on CALC
CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Nov 12, 2025, 7:01 AM EST - 22 days ago

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

Nov 12, 2025, 7:00 AM EST - 22 days ago

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025

Nov 10, 2025, 7:00 AM EST - 24 days ago

CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025

CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™

Oct 14, 2025, 7:00 AM EDT - 7 weeks ago

CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™

CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 7:00 AM EDT - 3 months ago

CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Aug 12, 2025, 7:00 AM EDT - 4 months ago

CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

Jul 8, 2025, 7:00 AM EDT - 5 months ago

CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure

Jun 25, 2025, 7:00 AM EDT - 5 months ago

CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure

CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting

Jun 12, 2025, 7:00 AM EDT - 6 months ago

CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting

CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

May 14, 2025, 7:00 AM EDT - 7 months ago

CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Presentations at Upcoming Medical Meetings

Apr 17, 2025, 7:00 AM EDT - 8 months ago

CalciMedica Announces Presentations at Upcoming Medical Meetings

CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference

Apr 1, 2025, 7:00 AM EDT - 8 months ago

CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference

CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates

Mar 27, 2025, 7:00 AM EDT - 9 months ago

CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Secures Credit Facility for Up to $32.5 Million

Mar 5, 2025, 7:00 AM EST - 9 months ago

CalciMedica Secures Credit Facility for Up to $32.5 Million

CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference

Mar 4, 2025, 7:00 AM EST - 9 months ago

CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference

CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference

Feb 19, 2025, 7:00 AM EST - 10 months ago

CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference

CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 4:05 PM EST - 10 months ago

CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors

Jan 14, 2025, 7:00 AM EST - 11 months ago

CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors

CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 8:00 AM EST - 1 year ago

CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference

CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Nov 13, 2024, 7:00 AM EST - 1 year ago

CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer

Nov 7, 2024, 7:00 AM EST - 1 year ago

CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer

CalciMedica Announces Pricing of Public Offering of Common Stock

Oct 30, 2024, 10:11 PM EDT - 1 year ago

CalciMedica Announces Pricing of Public Offering of Common Stock

CalciMedica Announces Proposed Public Offering of Common Stock

Oct 30, 2024, 4:50 PM EDT - 1 year ago

CalciMedica Announces Proposed Public Offering of Common Stock

CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

Oct 30, 2024, 7:00 AM EDT - 1 year ago

CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Oct 28, 2024, 4:05 PM EDT - 1 year ago

CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

Oct 16, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:00 AM EDT - 1 year ago

CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference

CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Aug 12, 2024, 4:10 PM EDT - 1 year ago

CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)

Jul 9, 2024, 7:30 AM EDT - 1 year ago

CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)

CalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences

Jul 8, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences

CalciMedica Set to Join Russell Microcap® Index

Jul 1, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Set to Join Russell Microcap® Index

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Jun 27, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Jun 26, 2024, 4:05 PM EDT - 1 year ago

CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

May 13, 2024, 4:05 PM EDT - 1 year ago

CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024

May 7, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024

CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis

Apr 24, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis

CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates

Mar 28, 2024, 7:00 AM EDT - 1 year ago

CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Mar 13, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Feb 28, 2024, 6:57 PM EST - 1 year ago

CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury

Feb 13, 2024, 8:00 AM EST - 1 year ago

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury

CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 4:05 PM EST - 1 year ago

CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

CalciMedica Announces Private Placement of up to Approximately $55 Million

Jan 22, 2024, 8:00 AM EST - 2 years ago

CalciMedica Announces Private Placement of up to Approximately $55 Million

CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

Nov 9, 2023, 7:00 AM EST - 2 years ago

CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition

Nov 2, 2023, 9:15 AM EDT - 2 years ago

CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition

CalciMedica Announces Upcoming Presentations and Events in September

Sep 6, 2023, 7:30 AM EDT - 2 years ago

CalciMedica Announces Upcoming Presentations and Events in September

CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023

Aug 31, 2023, 7:30 AM EDT - 2 years ago

CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023

CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Aug 9, 2023, 7:30 AM EDT - 2 years ago

CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

CalciMedica Announces Relisting on Nasdaq

Jun 12, 2023, 7:30 AM EDT - 2 years ago

CalciMedica Announces Relisting on Nasdaq

CalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP)

Jun 6, 2023, 7:30 AM EDT - 2 years ago

CalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP)

Life Biosciences Expands Team with the Appointment of Ming Yang, Ph.D., as SVP of Research and Development

May 23, 2023, 8:00 AM EDT - 2 years ago

Life Biosciences Expands Team with the Appointment of Ming Yang, Ph.D., as SVP of Research and Development

Elegant_Confusion
Elegant_Confusion Dec. 5 at 12:06 AM
$CALC something looks fishy when somebody trades a stock after hours way below market, and just minutes before after hours trading closes. There is no news to explain such a dive in the price. CALC is a very thinly traded stock! Someone could be selling to themselves using two accounts. Then in premarket trading, offer to buy more at a lowball bid, and see how many scared sellers take you up on it.
0 · Reply
Elegant_Confusion
Elegant_Confusion Dec. 4 at 11:36 PM
$CALC can anyone assess the reason for the sudden 15% slump in the after hour’s price, which appears to have taken place just minutes before after hours trading closed? How much volume did it represent?
1 · Reply
Gashcooper
Gashcooper Dec. 4 at 9:46 PM
$CALC No complaints from me🤷🏾‍♂️ - https://m.investing.com/news/analyst-ratings/oppenheimer-reiterates-outperform-rating-on-calcimedica-stock-ahead-of-key-trial-93CH-4385648?ampMode=1
0 · Reply
InfinityVenom
InfinityVenom Dec. 4 at 4:13 PM
$CALC Multi year breakout happening now. $SPY $QQQ
1 · Reply
Tfizzle
Tfizzle Dec. 4 at 2:27 PM
$EP $TPVG $CALC big insider buying all of these $MAIA $PFE
0 · Reply
Tfizzle
Tfizzle Dec. 3 at 8:07 PM
$CALC yup
0 · Reply
InfinityVenom
InfinityVenom Dec. 3 at 4:12 PM
$CAPR Mark my WORDS. $CALC is NEXT
1 · Reply
Tfizzle
Tfizzle Dec. 3 at 3:40 PM
$CALC pullback. Slingshot engaged!
0 · Reply
InfinityVenom
InfinityVenom Dec. 2 at 9:07 PM
$CALC Hell yea boys
0 · Reply
sh64
sh64 Dec. 2 at 8:55 PM
$CALC it’s time
0 · Reply
RedDogSailor
RedDogSailor Dec. 2 at 8:42 PM
$CALC Yep. Something big coming.
0 · Reply
Tfizzle
Tfizzle Dec. 2 at 8:12 PM
$CALC let’s do this
0 · Reply
Tfizzle
Tfizzle Dec. 2 at 7:59 PM
$CALC $5 soon
0 · Reply
MUBSN
MUBSN Dec. 2 at 6:54 PM
$AITX Biotech $CALC using AI to review trial data
0 · Reply
Sttst219
Sttst219 Dec. 2 at 6:12 PM
$CALC explains last Thursday, but who is Jorey Chernett? https://www.sec.gov/Archives/edgar/data/1534133/000204207725000016/xslSCHEDULE_13G_X01/primary_doc.xml
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Nov. 25 at 3:24 PM
$CALC $4.49 High I alerted when I was buying 🌞🌞🌞🌞
0 · Reply
Regzw
Regzw Nov. 25 at 3:12 PM
$DNUT $CALC
0 · Reply
Regzw
Regzw Nov. 25 at 3:12 PM
$SOUN $CALC check it out !!
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Nov. 25 at 2:29 PM
$CALC Adds!
0 · Reply
GSP
GSP Nov. 25 at 12:30 PM
$AEHL $CALC $ONDS $BFLY $AMTM
0 · Reply
BioTechHealthX
BioTechHealthX Nov. 25 at 9:16 AM
$CALC CalciMedica Inc. (NASDAQ:CALC) is gaining investor attention as its Auxora Phase 2 KOURAGE trial moves toward key 2026 results. With a $45.5M market cap and breakthrough data showing kidney function improvement and reduced IL-17, CALC could be one of the most undervalued biotech stocks to watch. https://biotechhealthx.com/biotech-news/calcimedica-calc-advances-phase-2-trial-for-acute-kidney-injury/
0 · Reply
SwingTradesOnly
SwingTradesOnly Nov. 25 at 1:48 AM
$CALC you're back up to July level. now what?
0 · Reply